Results from an open label, multicenter phase I #trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of #ASTX660 in combination with the anti-PD-1 antibody #pembrolizumab for solid #tumors doi.org/10.1038/s414...